LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

Inclusion Criteria:

* Histologically documented metastatic or locally unresectable clear cell renal carcinoma. In patients with mixed histologies, the clear cell component must comprise \> 75% of the cancer.
* Documented disease progression or intolerance while receiving treatment with: a) sunitinib, sorafenib, or both, and b) temsirolimus.
* Maximum of 4 prior systemic regimens allowed and may include other targeted agents, immunotherapy and chemotherapy.
* Measurable disease by RECIST criteria.
* ECOG PS 0 or 1.
* Laboratory values as follows: ANC \>= 1500/μL, Hgb \>= 9 g/dL, Platelets \>= 100,000/uL, AST/SGOT and ALT/SGPT \<= 2.5 x ULN or \<= 5.0 x ULN in patients with liver metastases, Creatinine \<= 2.0 mg/dL Or Calculated Creatinine Clearance \>= 50 ml/min, Albumin \>= 3 g/dL, Potassium \>= lower limit normal (LLN),Phosphorous \>= LLN, Calcium \>= LLN, Magnesium \> LLN
* Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment.
* Life expectancy \> 12 weeks.
* Accessible for treatment and follow-up.
* All patients must be able to understand the nature of the study and give written informed consent prior to study entry.

Exclusion Criteria:

* Age \< 18 years of age.
* Prior treatment with an HDAC inhibitor.
* Impaired cardiac function
* Ongoing therapy with antiarrhythmics or other medications associated with QTc prolongation.
* Uncorrected hypokalemia or hypomagnesemia.
* Uncontrolled hypertension or cardiac arrhythmias.
* Active parenchymal brain metastases. Patients who have had brain metastases resected, or have received radiation therapy ending \> 8 weeks prior to study entry are eligible if they meet all of the following criteria: 1) residual neurologic symptoms \< grade 1, 2) no dexamethasone requirement, 3) follow-up MRI shows regression of lesions after treatment, with no new lesions appearing.
* Active meningeal metastases.
* Known diagnosis of human immunodeficiency virus (HIV) infection.
* Unresolved diarrhea \> CTCAE grade 1.
* Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.
* Chemotherapy, investigational drug therapy, major surgery \< 4 weeks prior to starting study drug or patients that have not recovered from side effects of previous therapy.
* Patient is \< 5 years free of another primary malignancy except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
* Concomitant use of any anti-cancer therapy or radiation therapy.
* Pregnant or breast feeding or female of reproductive potential not using 2 effective methods of birth control.
* Male patients whose sexual partners are women of childbearing potential not using effective birth control.
* Patients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease.
* Other concurrent severe, uncontrolled infection or intercurrent illness
* Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known hypothyroidism who are stable on thyroid replacement are eligible.